DK2419086T3 - Biotilgængelige sammensætninger af amorf alpha-(n-sulfonamid)acetamidforbindelse - Google Patents

Biotilgængelige sammensætninger af amorf alpha-(n-sulfonamid)acetamidforbindelse

Info

Publication number
DK2419086T3
DK2419086T3 DK10714413.1T DK10714413T DK2419086T3 DK 2419086 T3 DK2419086 T3 DK 2419086T3 DK 10714413 T DK10714413 T DK 10714413T DK 2419086 T3 DK2419086 T3 DK 2419086T3
Authority
DK
Denmark
Prior art keywords
amorph
sulphonamide
bio
alpha
acetamide compound
Prior art date
Application number
DK10714413.1T
Other languages
Danish (da)
English (en)
Inventor
Ruiling F Hartley
Raja M Haddadin
Feng Qian
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DK2419086T3 publication Critical patent/DK2419086T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK10714413.1T 2009-04-14 2010-04-12 Biotilgængelige sammensætninger af amorf alpha-(n-sulfonamid)acetamidforbindelse DK2419086T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16906609P 2009-04-14 2009-04-14
PCT/US2010/030679 WO2010120662A2 (en) 2009-04-14 2010-04-12 Bioavailable compositions of amorphous alpha-(n-sulfonamido)acetamide compound

Publications (1)

Publication Number Publication Date
DK2419086T3 true DK2419086T3 (da) 2013-09-30

Family

ID=42664672

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10714413.1T DK2419086T3 (da) 2009-04-14 2010-04-12 Biotilgængelige sammensætninger af amorf alpha-(n-sulfonamid)acetamidforbindelse

Country Status (21)

Country Link
US (1) US20100261768A1 (enExample)
EP (1) EP2419086B1 (enExample)
JP (1) JP2012524090A (enExample)
KR (1) KR20120027142A (enExample)
CN (1) CN102387788B (enExample)
AR (1) AR076306A1 (enExample)
AU (1) AU2010236701A1 (enExample)
BR (1) BRPI1012523A2 (enExample)
CA (1) CA2758709A1 (enExample)
DK (1) DK2419086T3 (enExample)
EA (1) EA201171207A1 (enExample)
ES (1) ES2426403T3 (enExample)
HR (1) HRP20130807T1 (enExample)
MX (1) MX2011010513A (enExample)
NZ (1) NZ595411A (enExample)
PL (1) PL2419086T3 (enExample)
PT (1) PT2419086E (enExample)
SI (1) SI2419086T1 (enExample)
SM (1) SMT201300106B (enExample)
TW (1) TW201043269A (enExample)
WO (1) WO2010120662A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1289469C (zh) 2001-12-20 2006-12-13 布里斯托尔-迈尔斯斯奎布公司 α－(N－磺酰氨基)乙酰胺衍生物作为β－淀粉样蛋白抑制剂
US8044077B2 (en) 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
US8252821B2 (en) 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
AR087277A1 (es) * 2011-07-21 2014-03-12 Bristol Myers Squibb Co Composiciones biodisponibles de compuestos amorfos de piperidinilo, composicion farmaceutica, metodos
US20150045353A1 (en) * 2013-08-09 2015-02-12 Neurogenetic Pharmaceuticals, Inc. Formulations containing gamma secretase modulators, methods for preparation and delivery thereof
TWI765410B (zh) 2014-08-08 2022-05-21 日商中外製藥股份有限公司 ４環性化合物的非晶質體的用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3999007A (en) * 1975-10-09 1976-12-21 Carl Joseph Crane Aircraft visual approach/landing reproducer device and system
US5136301A (en) * 1989-08-30 1992-08-04 Rockwell International Corporation Primary flight display system having a vertical linear altimeter
US5274094A (en) * 1990-08-15 1993-12-28 British Bio-Technology Limited Production of heterobicyclic containing benzene sulfonamides
GB9202791D0 (en) * 1992-02-11 1992-03-25 British Bio Technology Compounds
DE69606804T2 (de) * 1995-06-20 2000-06-15 Honeywell, Inc. Integriertes System zur Grundkollisionsvermeidung
US5977141A (en) * 1995-11-17 1999-11-02 Warner-Lambert Company Sulfonamide inhibitors of matrix metalloproteinases
US6233522B1 (en) * 1998-07-06 2001-05-15 Alliedsignal Inc. Aircraft position validation using radar and digital terrain elevation database
US6313123B1 (en) * 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
US6570531B1 (en) * 2000-04-27 2003-05-27 Rockwell Collins, Inc. Satellite navigation receiver designed for compatibility with aircraft automatic landing systems
US6483454B1 (en) * 2000-11-28 2002-11-19 Bae Systems Aerospace Inc. Close formation aircraft collision avoidance
CN1289469C (zh) * 2001-12-20 2006-12-13 布里斯托尔-迈尔斯斯奎布公司 α－(N－磺酰氨基)乙酰胺衍生物作为β－淀粉样蛋白抑制剂
CN101274926A (zh) * 2003-03-31 2008-10-01 惠氏公司 β淀粉样蛋白生成抑制剂含氟和三氟烷基杂环磺酰胺及其衍生物
US20050048112A1 (en) * 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
FR2870605B1 (fr) * 2004-05-18 2010-10-08 Airbus France Procede et dispositif de guidage automatique d'un aeronef, pour un vol au moins en partie a basse altitude
FR2880456B1 (fr) * 2005-01-03 2007-02-23 Airbus France Sas Procede et dispositif d'alerte sonore lors de la desactivation d'un pilote automatique d'un aeronef
FR2886439B1 (fr) * 2005-05-24 2010-11-05 Eurocopter France Procede et dispositif d'aide au pilotage d'un aeronef a basse altitude
CN101384250A (zh) * 2005-11-09 2009-03-11 诺瓦提斯公司 利用临时增塑剂制备药物组合物的方法
FR2897448B1 (fr) * 2006-02-14 2008-03-14 Airbus France Sas Procede et systeme d'aide au pilotage d'un aeronef.
JP2009528281A (ja) * 2006-02-17 2009-08-06 ワイス スルホンアミド置換アルコールおよびその中間体の調製方法
TW200732295A (en) * 2006-02-17 2007-09-01 Wyeth Corp Selective N-sulfonylation of 2-amino trifluoroalkyl substituted alcohols
WO2007109604A2 (en) * 2006-03-20 2007-09-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
US20070218012A1 (en) * 2006-03-20 2007-09-20 Bittorf Kevin J Pharmaceutical Compositions
FR2911988B1 (fr) * 2007-01-26 2016-03-25 Airbus France Procede et dispositif pour determiner une hauteur maximale de stabilisation lors de la phase finale de vol d'un avion
US8084477B2 (en) * 2007-10-31 2011-12-27 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production

Also Published As

Publication number Publication date
MX2011010513A (es) 2011-11-29
PL2419086T3 (pl) 2013-11-29
ES2426403T3 (es) 2013-10-23
WO2010120662A3 (en) 2011-09-15
EP2419086B1 (en) 2013-06-26
CN102387788B (zh) 2013-07-10
PT2419086E (pt) 2013-09-04
TW201043269A (en) 2010-12-16
AU2010236701A1 (en) 2011-10-20
US20100261768A1 (en) 2010-10-14
SMT201300106B (it) 2013-11-08
SI2419086T1 (sl) 2013-10-30
BRPI1012523A2 (pt) 2016-03-29
EP2419086A2 (en) 2012-02-22
KR20120027142A (ko) 2012-03-21
CN102387788A (zh) 2012-03-21
AR076306A1 (es) 2011-06-01
NZ595411A (en) 2013-02-22
HRP20130807T1 (hr) 2013-09-30
CA2758709A1 (en) 2010-10-21
EA201171207A1 (ru) 2012-03-30
JP2012524090A (ja) 2012-10-11
WO2010120662A2 (en) 2010-10-21

Similar Documents

Publication Publication Date Title
DK2403512T3 (da) Sammensætninger af polymer myrcen
DK2567524T3 (da) Reduktion af protokolspild
PL2214679T3 (pl) Kompozycje kortykosteroidów
DK2011486T3 (da) Farmaceutiske sammensætninger af rifaximin
DK3078664T3 (da) Antiparasitiske dihydroazol-sammensætninger
EP2488022A4 (en) Compositions
UY33161A (es) Composiciones plaguicidas
EP2470605A4 (en) Cured polyhydroxyalkanoate compositions
BR112012005237A2 (pt) utilização de composições ternárias
DK2421537T3 (da) Pyrazolylaminopyridiner som inhibitorer af FAK
DK2262793T3 (da) Krystallinske former af nilotinib-hci
DOP2011000396A (es) Composiciones novedosas
DK2498756T3 (da) Tabletformuleringer af neratinibmaleat
EP2167043A4 (en) NEW USE CO-CRYSTAL COMPOSITIONS
EP2136768A4 (en) Structured surfactant compositions
DK2634232T3 (da) Sammensætninger
LT3403654T (lt) Geriamosios kortikosteroido kompozicijos
DK3208269T3 (da) Inhibitorer af c-fms-kinase
BRPI1010690A2 (pt) composições
DK2111555T3 (da) Diagnosticering af præeklampsi
DK2358714T3 (da) Alkylcyclohexylethere af dihydrotetraazabenzoazulener
LT2966175T (lt) Farmacinės kompozicijos turinčios korteksolono-17-alfa-propionato
DK2408446T3 (da) Anvendelse af farmaceutiske sammensætninger, der indeholder mesembrenon
DK3284820T3 (da) Fremgangsmåde til behandling af pyropheophytin-holdige sammensætninger
DK2459129T3 (da) Forbedringer af karstøtteanordninger